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Abstract: Multiple sclerosis (MS) affects young adults during the most productive years of 
their lives, and until recently many neurologists were limited to treating symptoms and attacks 
without any ability to alter the disease course. The 1990s ushered in an era of possibility 
with the approval of three interferon-beta (IFNβ) therapies for the treatment of MS. Though 
the mechanism of action of these agents is not completely understood, it is clear they reduce 
magnetic resonance imaging (MRI) activity as well as improve clinical outcomes. The principal 
randomized, blinded, multicenter trials of IFNβ all point to the need for early treatment soon 
after the diagnosis of MS is made. Efficacy has also been shown in patients treated after a first 
demyelinating event. Data on IFNβ in the treatment of secondary progressive MS (SPMS) is not 
impressive, although it shows some benefit in SPMS patients who continue to experience MRI 
activity and clinical relapses, signifying a continued inflammatory component to their disease. 
There has been no proven efficacy of IFNβ in the treatment of primary progressive MS (PPMS). 
The IFNβ therapies are generally well tolerated with a favorable side effect profile. Despite 
benefits in MRI and clinical measures such as relapse rates and Expanded Disability Status 
Scale progression, patients continue to exhibit clinical progression and radiological atrophy, 
pointing to confounding factors and perhaps multiple etiologies of a disease that is not yet fully 
understood. In addition, the subject of neutralizing antibodies has recently assumed importance. 
The significance of these on treatment efficacy is uncertain, and until a universally accepted 
reliable assay is adopted, the decision to change treatment continues to rely on the clinical 
interpretation of the patient’s history and physical examination. Additional recommendations 
for management of patients, informed by the best available evidence, are also presented.
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Introduction
Multiple sclerosis (MS) is characterized by unpredictable signs and symptoms involving 
the sensory, motor, visual, and brainstem systems. Recently, cognitive and mood 
disturbances have also become more widely recognized in these patients. The disease 
is also highly variable in terms of the frequency and severity of attacks, as well as the 
extent and rate of progression of disability. Despite this unpredictability, neurologists 
categorize patients into one of four forms based on disease course. The currently accepted 
classification of MS into four forms was established by an international survey.1 The 
most common form is relapsing remitting MS (RRMS), which accounts for 85% of MS 
cases at onset. This is characterized by relapses, also known as attacks or exacerbations, 
followed either by full recovery, or a residual neurological deficit. Relapses are defined 
as neurologic symptoms lasting more than 24 hours, preceded by at least one month Biologics: Targets & Therapy 2009:3 258
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of stability, and accompanied by a change in the neurologic 
examination that cannot be explained by an infection or other 
illness. The time between attacks is characterized as a remis-
sion or lack of disease progression whether or not the patient’s 
neurologic status returns to baseline. Approximately 50% of 
RRMS patients will go on to develop secondary progressive 
MS (SPMS) within 10 years. SPMS is defined by an initial 
relapsing remitting course, followed by gradual progression 
with or without occasional relapses or plateaus. These patients 
are usually more disabled than RRMS patients, and the dis-
ability results from incomplete recovery from exacerbations 
as well as steady progression.
Patients with primary progressive MS (PPMS) make up 
approximately 10% of the population. PPMS patients have disease 
progression from onset, sometimes with infrequent plateaus or 
minor improvements. The hallmark of PPMS is continued 
worsening of the baseline without clear relapses. Progressive 
relapsing MS (PRMS) is the rarest form, compromising approxi-
mately 5% of MS patients. These individuals have a progressive 
course from disease onset with one or more superimposed acute 
relapses, following which the progression continues. A related 
condition is the clinically isolated syndrome (CIS), defined as a 
single demyelinating event suggestive of an initial MS attack. 
These patients are at risk of developing RRMS, but do not meet 
currently accepted criteria for MS because of a lack of clinical 
or radiologic episodes separated in time and space. Patients with 
T2 magnetic resonance imaging (MRI) lesions at onset have a 
substantially greater risk of developing MS and progression of 
disability, than those with normal MRI scans.2
Treatment of MS patients can be divided into three types: 
acute, disease-modifying, and symptomatic. Prior to the early 
1990s, management of MS patients was limited to acute 
and symptomatic treatment, leaving neurologists at a loss 
as to what to do between attacks. In 1993, the first disease-
modifying agent for the treatment of MS was approved by 
the US Food and Drug Administration (FDA), and over the 
course of the next few years, two other IFNβ agents gained 
FDA approval for treatment of relapsing forms of MS. 
There is still much to be learned regarding the pathogenesis 
of this disease, one clear aspect being that a component of 
immune dysregulation occurs which responds moderately 
well to immunomodulating treatment. A complete review 
of all the disease-modifying therapies, or even all aspects of 
IFNβ, is beyond the scope of this review. Our aim, rather, 
is to address briefly the proposed mechanisms of action of 
the IFNβ preparations, describe their proven efficacy and 
safety in clinical trials, discuss the importance of neutralizing 
antibodies and other safety issues, and conclude with 
therapeutic recommendations based on these factors, and on 
our own experience, for the treatment of patients with MS.
Mechanism of action
Experimental evidence supports the hypothesis that the MS 
disease process is due, at least in part, to autoimmunity.3–5 
The currently prevalent theory involves the activation of 
autoreactive type 1 T helper (Th1) cells in the peripheral 
immune system. Th1 cells are exposed either to self antigens 
or to molecules that closely mimic them, and become 
activated in the presence of co-stimulatory molecules, 
leading to the release of proinflammatory cytokines such 
as interleukin 12 (IL-12), IL-17, interferon gamma (IFNγ), 
and tumor necrosis factors. Associated with this, there is an 
up-regulation of adhesion molecules allowing for binding 
of T cells and transmigration across the endothelial surface 
of CNS venules. The activated T cells then attack the 
basement membrane component of the blood–brain barrier 
(BBB) by secreting matrix metalloproteinases (MMP), 
proteolytic enzymes that increase BBB permeability and 
allow for passage of the T cell into the CNS. This process is 
then amplified upon entry into the CNS by presentation of 
myelin autoantigens and further production of inflammatory 
cytokines, leading to the destruction of myelin and axons. 
This is, of course, a greatly simplified view of the process, 
many aspects of which are still under investigation.
There are multiple mechanisms by which IFNβ is 
proposed to work, beginning with down regulation of major 
histocompatibility complex type 2 (MHC II) expression. The 
antigen-MHC II complex is recognized on the surface of an 
antigen presenting cell by a Th1 cell, leading to activation. 
Downregulation of MHC II leads to decreased presentation 
of self antigens and decreased Th1 activation. IFNγ, a 
pro-inflammatory cytokine, usually up-regulates MHC II 
complexes and IFNβ is thought to interfere with this process.6 
IFNβ also affects IFNγ another way, by decreasing its release 
from activated T cells.7 IFNβ has been shown to decrease 
the co-stimulatory molecules necessary to activate T cells,8 
and may also bring about a shift from a pro-inflammatory 
(Th1) state to an anti-inflammatory state characterized 
by proliferation of type 2 (Th2) T helper cells. A recent 
study showed a shift of cytokines from those that promote 
inflammation, eg, IL-12, to anti-inflammatory cytokines, 
such as IL-10, thus supporting a shift from a Th1 to a Th2 
type milieu.9
IFNβ can affect BBB permeability to cells and proteins 
via multiple mechanisms, the most important of which is 
probably inhibition of MMP production by T cells, thereby Biologics: Targets & Therapy 2009:3 259
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preventing breakdown of the subendothelial extracellular 
matrix and passage of activated T cells into the CNS.10,11 
This effect is most vividly demonstrated by the dramatic 
reduction in gadolinium-enhancing lesions seen on MRI 
almost immediately after treatment with IFNβ is begun.12 
Interferons were also recently found to demonstrate a direct 
stabilizing effect on endothelial cells in vitro limiting the 
migration of small particles into the CNS.13 Another potential 
mechanism involves the adhesion of activated T cells to 
the endothelial surface. Patients receiving IFNβ have been 
shown to produce soluble vascular cell adhesion molecule 
(VCAM), corresponding to a reduction in contrast enhancing 
lesions on MRI.14,15 Thus soluble VCAM may act as a decoy, 
binding to activated T cells and keeping them from crossing 
into the CNS.
IFNβ also inhibits the expansion of T cell clones16 and 
was found to increase T cell death through inhibition of FLIP, 
an antiapoptotic protein.17 Other investigators have focused 
on regulation of cytokine and growth factor production in 
MS. For example, IFNβ may promote production of the 
suppressive cytokine IL-10 by activated T cells in early MS, 
but not in later stage progressive forms of the disease.18 Effects 
on IFNγ and brain-derived neurotrophic factor (BDNF) have 
also been studied, with interesting but sometimes paradoxical 
results that require further analysis.19
Researchers have also turned their attention to molecular 
mechanisms by which interferon therapy may exert its 
action. Because interferons act by promoting gene activation 
via intracellular transcription factors, changes in mRNA 
expression can be identified in patients exposed to interferon 
therapy. Many studies, eg,20 have focused on expression of 
genes thought to be involved in MS. Recently, however, 
investigators have attempted to cast a broader net, using 
cDNA microarrays to detect changes in gene expression 
related to IFNβ therapy,21 or to identify responders and non-
responders to IFNβ therapy.22 Although this area of research 
is preliminary, it may represent an important step toward 
linking MS etiology and therapy.23
Currently, there are two forms of IFNβ approved for the 
treatment of MS, both of which are produced by recombinant 
DNA technology. IFNβ-1a (Avonex®, Biogen Idec and 
Rebif®, Merck Serono) is produced in Chinese hamster 
ovary cell lines. These molecules are glycoproteins with a 
166 amino acid sequence, identical to that of human IFNβ; 
however, the glycosylation patterns are different, and not 
necessarily identical to those found in human IFN-β. IFNβ-1b 
(Betaseron®, Bayer HealthCare or Betaferon®, Schering 
AG) is produced in an Escherichia Coli cell line and is not 
glycosylated, as bacteria cannot glycosylate proteins. IFNβ-1b 
has an amino acid substitution, serine for cysteine at position 
17, to prevent aggregation and preserve proper folding and 
biologic function. This molecule also differs slightly from 
IFNβ-1a in length, as it contains only 165 amino acids due 
to deletion of the N-terminal methionine. The differences 
between IFNβ-1b and IFNβ-1a have certain consequences 
that are thought to be important, such as lower specific 
activity of IFNβ-1b, as well as an increased tendency to 
neutralizing antibody (NAb) formation in patients treated 
with IFNβ-1b. The 1990s saw several randomized control-
led trials addressing the efficacy of IFNβ in the treatment of 
multiple sclerosis. Tables 1 and 2 list the large multicenter 
studies for the treatment of MS and CIS with the different 
forms of IFNβ.24
Efficacy of IFNβ in MS
The first pilot study of IFNβ-1b for the treatment of MS was 
performed in the late 1980s.25 Thirty RRMS patients were 
randomized to receive 0.8, 4, 8, or 16 million international 
units (MIU) of IFNβ-1b or placebo via subcutaneous 
(SC) injection administered three times per week (TIW). 
The 8 MIU dose was reasonably well tolerated; however, the 
16 MIU caused excessive side effects. This study showed a 
dose dependent reduction in attacks, but an effect of treatment 
on disease progression could not be assessed.
A phase III trial of IFNβ-1b in MS was initiated in 
1988.26 The primary outcome measures were reduction in 
annual exacerbation rate and proportion of exacerbation free 
patients. Three hundred seventy-two clinically definite RRMS 
patients were enrolled at 11 centers in the United States and 
Canada. Patients were between the ages of 18 and 50, had a 
history of two exacerbations within the previous two years, 
and an Expanded Disability Status Scale (EDSS) score27 of 
5.5 or less. Subjects were randomized to receive placebo, 
high dose (8 MIU), or low dose (1.6 MIU) of IFNβ-1b by 
SC injection every other day. MRI scans were performed 
yearly with the exception of a subset of patients at a single 
site who were scanned every six weeks for the first two years 
to assess the effect of treatment more closely. This study was 
initially planned for two years, was subsequently extended 
to three years, and then to five years. The three-year data 
revealed statistically significant results in the treatment arms 
compared to placebo.26,28 The annual exacerbation rate for the 
high dose group (0.84) was less than for the placebo group 
(1.27), with a p value of 0.0001, approximately a one-third 
reduction in the frequency of exacerbations. Moderate and 
severe attacks were decreased by 50% compared to placebo. Biologics: Targets & Therapy 2009:3 260
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The number of exacerbation-free patients at two years was 
statistically significant in the high dose group; however this 
was not maintained at three years. The effect of IFNβ-1b on 
disease progression, as measured by change in EDSS scores, 
did not reach statistical significance. Inclusion of the low 
dose group revealed a dose-response effect, with values for 
most outcome measures falling between the placebo and 
high-dose groups.
Cumulative disease burden (an approximation of lesion 
volume) on MRI showed a highly significant effect of 
high dose IFNβ-1b compared to placebo (p = 0.002). MRI 
activity assessed by measuring new or enlarging lesions in 
the subset of patients undergoing frequent MRI scanning 
every six weeks for two years showed an 80% reduction of 
activity with high dose treatment. In a subsequent report29 
the median time on study for patients was 4 years, with a 
few reaching 5 years. When all data were pooled for all 
time points in the study, a 30% reduction in relapse rate 
persisted in the high dose treatment arm (0.78 per year 
compared with 1.12 for placebo; p = 0.0006). Although the 
exacerbation rates each year were approximately one-third 
lower in the high dose treatment arm, after year 2 this was 
not statistically significant, probably due to dropouts and loss 
of statistical power. The MRI efficacy of IFNβ-1b persisted 
through year 5, with no significant increase in lesion burden. 
The study was not powered to show a significant effect on 
disease progression. Both doses of IFNβ-1b were tolerated 
well enough for the FDA to grant approval without undue 
concern for serious adverse events.
IFNβ-1b was subsequently tested in patients with SPMS 
with conflicting results in two placebo-controlled multi-
center randomized studies. In the European study,30 718 
patients with SPMS and EDSS scores of 3.0 to 6.5, with 
confirmed progression or at least two exacerbations in the 
prior two years, were randomized to either 8 MIU of IFNβ-1b 
or placebo every other day. The primary outcome was time 
to confirmed progression of disability, as measured by a 
one-point increase on the EDSS, sustained for three months 
(or a 0.5-point increase if the baseline EDSS was 6.0 or 6.5). 
The study was terminated shortly before its planned end point 
of three years because of statistically convincing evidence 
of efficacy. A significant difference in time to confirmed 
progression was found in favor of IFNβ-1b (p = 0.0008). The 
IFN group had a 21.7% reduction in rate of progression, or a 
12-month delay in reaching similar disability levels compared 
with placebo. This effect was also seen in time to becoming 
wheelchair bound (EDSS 7.0 or greater) being delayed by 
nine months. There were significant reductions in relapse 
rates and in MRI activity as measured by contrast enhancing 
lesions; however, there was no reduction in brain atrophy. The 
results of this study led to the approval of IFNβ-1b in Europe 
and Canada for the treatment of patients with SPMS.
The second trial of IFNβ-1b in SPMS was performed 
in the United States and Canada.31 Patients eligible for 
randomization had EDSS scores of 3.0–6.5, and an increase 
in their EDSS scores of at least one point in the two years 
prior to screening. There was no relapse requirement other 
than a history of one relapse at some time in the past, to 
confirm the diagnosis of SPMS. Nine hundred thirty-nine 
patients were randomized to IFNβ-1b 8 MIU, or a variable 
dose of 5 MIU/m2, or to one of two matching placebo arms 
administered SC every other day. The planned outcome 
measures were the same as in the European study. This trial 
was planned for a three year end-point, but was stopped 
early because an interim data analysis indicated the inability 
to achieve a significant difference in the primary outcome 
measure. In contrast to the European study, treatment with 
IFNβ-1b did not improve disability measures compared 
with placebo. Consistent with previous studies, there was a 
significant reduction in the already low relapse rates and in 
MRI measures of activity.
The disparity between these two studies has been the 
subject of much debate. When differences in baseline 
demographics were analyzed,32 patients in the European trial 
were found to be younger, to have higher relapse rates prior 
to entry, shorter disease duration, and a higher proportion 
of contrast enhancing lesions. The entry criteria for these 
two studies may have added to the differences seen, as the 
European trial required either two relapses or a one-point 
increase in the EDSS over two years to document disease 
progression, whereas the North American trial excluded 
patients with relapses and required a one-point deterioration 
in two years. In the European study, this may have selected 
for patients earlier in the disease course, characterized by 
more intense inflammation, and therefore a greater tendency 
to respond to IFNβ-1b. Kappos and colleagues (2004) also 
remarked on the lack of approved therapies in Europe for 
the treatment of MS at the time of enrollment in the trial. In 
North America, during enrollment of the SPMS trial there 
was already one approved immunomodulatory therapy, and 
two others became available during the course of the study. 
Thus, patients in the North American group may have been 
preselected for a lower likelihood of responding to IFNβ-1b. 
The authors of the retrospective analysis concluded that 
SPMS patients with continuing superimposed relapses may 
be more likely to benefit from IFNβ-1b treatment.Biologics: Targets & Therapy 2009:3 262
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The efficacy and tolerability of IFNβ-1b in the treatment 
of clinically isolated syndromes (CIS) was recently reported.33 
The Betaferon in Newly Emerging Multiple Sclerosis 
for Initial Treatment (BENEFIT) trial was a multicenter, 
randomized, double-blind, placebo controlled trial assessing 
the effect of treatment on the rate of conversion to clinically 
definite MS (CDMS) as defined by the Poser criteria34 and 
furthermore, as defined by the newer McDonald criteria.35 Four 
hundred sixty-eight patients with a first clinical demyelinating 
event (either monosymptomatic or polysymptomatic) and 
at least two clinically silent MRI lesions were randomized 
in a five to three ratio to receive either 8 MIU of IFNβ-1b 
or placebo subcutaneously every other day. Exacerbations 
were documented by an examining physician and when the 
diagnosis of CDMS was confirmed, the patient was offered 
open-label treatment. IFNβ-1b significantly delayed the 
onset of CDMS and “McDonald MS” (p  0.0001). At the 
end of the two year study, the probability of not developing 
“McDonald MS” was twice as high with IFNβ-1b (31%) as 
with placebo (15%). IFNβ-1b significantly reduced MRI 
activity and was well tolerated, as indicated by the low 
dropout rate (7.2%) in the IFNβ-1b group.
Following the two year placebo-controlled phase, patients 
were eligible to enter an open-label follow-up phase and 
were offered IFNβ-1b 250 µg subcutaneously every other 
day for up to five years from randomization.36 Follow-up 
visits occurred every six months with a blinded examiner 
performing a standardized neurological assessment and 
EDSS score. The primary outcomes of this analysis were time 
to diagnosis of CDMS, time to confirmed EDSS progression, 
and score on a patient-reported functional assessment 
scale. Eighty-nine percent of patients entered the follow-up 
phase with 84% completing three years. At that time, early 
treatment was shown to reduce the risk of developing CDMS 
by 41% (absolute risk reduction of 14%) compared to delayed 
treatment. More importantly, early treatment reduced the risk 
for progression of disability, as measured by a sustained one 
point change in the EDSS, by 40% compared to the delayed 
treatment group.
The pivotal trial of IFNβ-1a (Avonex®) was the first to 
use delay of disability, as measured by time to progression of 
the EDSS score by one point sustained for six months, as the 
primary outcome measure.37 The investigators enrolled 301 
relapsing MS patients with at least two exacerbations during 
the previous three years, and EDSS scores of 1.0 to 3.5. 
Patients were randomized to receive either IFNβ-1a 6 MIU 
(30 µg) or placebo by weekly intramuscular (IM) injection. 
This study was designed with a two-year end-point in mind; 
however, the number of dropouts was lower than anticipated, 
and the study was terminated early. Only 57% of patients 
completed two years, and 77% completed 18 months. Time 
to sustained progression was significantly greater in IFNβ-1a 
treated patients (21.9%) compared with placebo (34.9%) at 
104 weeks (p = 0.02). There was a significant reduction in 
relapse rates, most evident at the end of year 2. This reduction 
was 31% for those completing two years, but only 18% for 
all patients in the study.
A significant reduction in gadolinium enhancing lesions 
was present at year 1, and was maintained at year 2 (p = 0.02), 
but the effect on total T2 lesion volume was not significant. 
Tolerance of the drug was acceptable, considering the 
inherent discomfort of the IM injection route. Subsequent 
re-analysis of the data by the investigators38 included a change 
of EDSS greater than two points, or sustained progression by 
one point for one year, with the conclusion that the previous 
results underestimated the effect of IFNβ-1a. Further post-hoc 
analysis revealed benefit in some areas of neuropsychological 
testing and degree of brain atrophy in patients treated with 
IFNβ-1a.39,40
Although IM IFNβ-1a was modestly effective in the 
treatment of relapsing MS patients, the optimal dose was not 
established. A randomized, double-blind, dose-comparison 
study of weekly IFNβ-1a comparing 30 µg versus 60 µg by 
weekly IM injection was therefore conducted.41 The primary 
endpoint was six-month EDSS progression, and there 
were multiple other clinical and MRI secondary outcome 
measures. Eight hundred two relapsing MS patients with 
EDSS scores of 2.0 to 5.5 were enrolled and randomized to 
either treatment arm. At 36 months, there was no statistical 
difference between the two treatment arms in either primary 
or secondary endpoints. 608 patients completed 36 months, 
and 448 patients remained in an extension of the trial to 
48 months. At that time, there continued to be no statistical 
difference between the 30 µg and 60 µg weekly doses in terms 
of efficacy or safety.42 In the absence of a placebo group, the 
meaning of these findings is dubious.
The effect of IM IFNβ-1a in SPMS was evaluated in 
the International Multiple Sclerosis Secondary Progressive 
Avonex Clinical Trial (IMPACT), which enrolled 436 SPMS 
patients with progression over the previous year, and EDSS 
scores of 3.5 to 6.5.43 This trial was designed to determine 
whether 60 µg IFNβ-1a given once weekly by the IM route 
was more effective than placebo as measured by changes 
at two years in the MS Functional Composite (MSFC), a 
novel measure of disability.44 IFNβ-1a treatment reduced 
median MSFC worsening by 40% (p = 0.033). This effect Biologics: Targets & Therapy 2009:3 264
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was primarily driven by the nine-hole peg test and the paced 
auditory serial addition test. No benefit was seen on the 
EDSS, a secondary endpoint. Significant benefits in relapse 
rate and MRI outcomes were noted in IFN-treated subjects. 
This was the first study to use the MSFC to assess disability, 
but because it had not yet been validated as an outcome 
measure, the FDA refused to approve IM IFNβ-1a for the 
treatment of SPMS.
The Controlled High-Risk Avonex Multiple Sclerosis 
Prevention Study (CHAMPS) trial45 sought to determine 
whether patients with CIS treated with 30 µg of IFNβ-1a 
intramuscularly once weekly are less likely to develop CDMS. 
This randomized double-blind study enrolled 383 patients 
with a first isolated demyelinating event of optic neuritis, 
incomplete transverse myelitis, or brainstem – cerebellar 
dysfunction. Patients were also required to have two or more 
T2 signal abnormalities consistent with demyelination on 
their MRI scans. Patients were screened within two weeks 
of symptom onset and all received a three-day course of 
one gram of intravenous methylprednisolone followed by 
14 days of oral prednisone. Treatment with IFNβ-1a began 
within four weeks of the initial event. The primary out-
come measure was conversion to CDMS, which required 
documentation of new symptoms suggesting a relapse, and 
confirmation by a central end-point committee. MRI scans 
were performed every six months for the first 18 months, 
but were not required to confirm the diagnosis of CDMS. 
When CDMS was confirmed, subjects were removed from 
the study and offered treatment with IFNβ-1a. This trial 
was terminated early because of significant evidence of 
efficacy in the treatment group compared to controls. There 
was a cumulative probability of 50% of placebo patients 
having a second attack, compared to 35% of those treated 
with IFNβ-1a (p = 0.002). Changes in the volume of brain 
lesions on T2 weighted MRI were statistically significant 
in the treatment arm as well. Following publication of this 
study, the FDA approved the use of IM IFNβ-1a for the 
treatment of CIS.
In a small randomized controlled trial of PPMS patients 
treated with IFNβ-1a,46 fifty patients were randomized to 
weekly IM injections of IFNβ-1a at doses of 30 µg, 60 µg, 
or placebo for two years. The primary endpoint of sustained 
progression in disability was not met in either active treatment 
arm. Larger studies in PPMS have not been performed.
The pivotal study of IFNβ-1a (Rebif®) given by SC 
injection was PRISMS (Prevention of Relapses and Disability 
by Interferon β-1a Subcutaneously in Multiple Sclerosis), 
a multicenter, randomized, placebo controlled trial of 560 
patients with RRMS.47 Patients were eligible if they had had 
at least two relapses in the preceding two years and EDSS 
scores between 0 and 5.0. They were randomized to either 
22 µg, 44 µg, or placebo treatment arms, and were treated 
TIW for two years. The primary outcome measure was relapse 
count over the course of the study. Both treatment groups had 
significant reductions in relapse rate compared with controls, 
achieving 27% and 33% reductions for the 22 µg and 44 µg 
doses respectively over the study period (p  0.0002). Both 
doses also showed significance in percentage of relapse free 
patients, time to first relapse, and severity of relapses. Time to 
sustained progression was significantly longer (p  0.05) in 
both interferon IFNβ-1a treatment groups than in the placebo 
group. A composite score of integrated disability (area 
under the EDSS curve over time) showed a 77% reduction 
in accumulated burden of disability during the study. The 
number of enhancing lesions as well as T2 lesion volume 
on MRI were significantly lower in both treatment groups 
(p  0.0001).48 Although the higher dose group did better, 
there was no statistical difference between the two doses on 
major clinical outcomes.
After completion of the initial two-year PRISMS trial, 
the study was extended (PRISMS-4) and patients initially 
receiving placebo were re-randomized to either high or 
low dose IFNβ-1a.49 Those already on interferon therapy 
remained on their current dose. The primary outcome was 
relapse count per patient over four years. Ninety percent 
of patients randomized in the initial trial were enrolled in 
PRISMS-4. At the end of four years, there was continued 
evidence of efficacy, and a dose effect became more apparent, 
particularly on MRI outcomes. Most notably, confirmed 
progression of disability was lowest in the patients who took 
high dose IFNβ-1a for four years, and highest in those who 
received placebo for two years followed by low dose IFNβ-1a 
for the next two years. The effect was intermediate for the 
other two groups, supporting the idea of starting therapy as 
soon as possible after diagnosis.
A long-term follow up (LTFU) at 7–8 years of the 
PRISMS study was recently published.50 Sixty-eight percent 
(382/560) of patients from the original PRISMS trial 
returned for assessment. At LTFU, 80% of the cohort had 
not progressed to SPMS, and the mean T2 lesion load and 
relapse rate remained lowest in those treated with high dose 
IFNβ-1a for eight years. Interestingly, brain parenchymal 
volume, as a measure of atrophy, declined in all groups. This 
measurement was limited by the lack of a placebo cohort for 
the full duration of the study. The authors commented that 
brain parenchymal volume was a promising new measure Biologics: Targets & Therapy 2009:3 265
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of chronicity of disease, but that it could be confounded 
by physiologic fluctuations. Importantly, there were no 
new safety concerns identified and long-term safety and 
tolerability were maintained. The inherent weaknesses 
in LTFU studies should be considered when interpreting 
these results.
The Once Weekly Interferon for MS Study (OWIMS) 
ran nearly concurrently with the PRISMS study.51 This was 
a randomized, double-blind study of IFNβ-1a 22 µg, 44 µg, 
or placebo administered by SC injection weekly for one year. 
A total of 293 RRMS patients were enrolled. The primary 
outcome measure was the number of combined unique 
(CU) active lesions (PD/T2 or T1-enhancing) at 24 weeks. 
No clinical variables, other than steroid use in the 44 µg 
group, reached statistical significance. The MRI features 
of CU lesions and burden of disease significantly favored 
the treatment arms. The authors concluded that when taken 
together with other studies, a dose-effect relationship exists 
for both clinical and MRI variables.
In 2001, a trial of SC IFNβ-1a in SPMS was reported.52 
This study enrolled 618 patients in Europe, Canada, and 
Australia with EDSS scores of 3.0 to 6.5, a history of clinical 
progression for at least six months, and an increase in EDSS 
of one or more points in the two previous years (0.5 if the 
EDSS was 6.0–6.5). Subjects were randomized to receive 
22 µg, 44 µg, or placebo by SC injection TIW for three years. 
The study’s primary endpoint was time to confirmed disability 
progression, defined as an increase from baseline by at least 
1 EDSS point (0.5 if baseline greater than 5.5) confirmed 
three months later. The primary outcome measure was not 
statistically affected by treatment, as was also seen in the North 
American IFNβ-1b trial. There was a significant effect of 
treatment on relapse rates, and MRI measures including lesion 
load, and new or enlarging T2 lesions.53 A subgroup analysis 
suggested that maximal benefit with IFNβ-1a treatment in 
SPMS was seen in patients who continued to experience 
relapses, tending to confirm the outcomes of the European 
and North American IFNβ-1b studies.
A trial of IFNβ-1a in patients with CIS was reported 
by the Early Treatment of Multiple Sclerosis (ETOMS) 
Study Group.54 Eligible patients experienced their first 
event suggestive of monosymptomatic or polysymptomatic 
demyelinating disease within 3 months, had one or more 
abnormalities present on neurologic examination, and 
an MRI consistent with demyelinating disease. Steroid 
treatment of the initial attack was allowed only for moderate 
or severe exacerbations. Three hundred eight patients 
were randomized to either placebo or 22 µg IFNβ-1a by 
SC injection once weekly. The primary outcome measure 
was conversion to CDMS as defined by a second clinical 
relapse, confirmed when the evaluating physician could 
detect an objective change on neurologic examination. 
At the end of two years, 45% of placebo treated patients 
converted to CDMS, compared with 34% of those receiving 
active treatment (p = 0.047). The treatment arm showed a 
significant effect on the number of T2 lesions and total lesion 
volume. Subsequently, in a reanalysis of the data, Eilippi and 
colleagues55 reported a significant treatment effect on brain 
atrophy at two years compared to baseline (p = 0.0031). 
This study may be interpreted as showing that when MS 
is treated in its earliest stages, even a dose of IFNβ-1a that 
is considered subtherapeutic (22 µg once weekly) may be 
effective in preventing or delaying relapses.
Head-to-head studies
There have been three head-to-head trials of IFNβ therapy 
published to date. The longest of these was the INCOMIN 
(Independent Comparison of Interferons) trial, comparing 
every other day SC IFNβ-1b to once weekly IM IFNβ-1a.56 
Patients included in this study had clinically definite RRMS, 
EDSS scores between 1.0 and 3.5, and two documented 
relapses within the previous two years. One-hundred 
eighty-eight patients enrolled at 15 Italian centers were 
randomized to either IFNβ-1a 30 µg IM weekly or IFNβ-1b 8 
MIU SC every other day. The MRI evaluators were blinded, 
but clinical evaluators were not. The primary outcome 
measure was the proportion of relapse-free patients during the 
two years of study. The IFNβ-1b cohort showed a significant 
difference in freedom from relapses compared with IFNβ-1a 
(56% vs 36% p = 0.036), and a significant reduction in new 
T2 lesions on blinded MRI (p  0.0003).
In the EVIDENCE (Evidence of Interferon Dose-response: 
European North American Comparative Efficacy) trial,57 
investigators compared the efficacy and safety of once weekly 
IFNβ-1a 30 µg IM with high-dose IFNβ-1a 44 µg SC TIW. 
The 677 patients enrolled in this study had definite RRMS, 
EDSS scores of 0 to 5.5, were IFN naïve, and had experienced 
two or more exacerbations within the previous two years. 
The patients were aware of their treatment assignment, but 
evaluators of the clinical and MRI outcomes were blinded. 
The primary clinical endpoint was the proportion of relapse-
free patients, and the primary MRI endpoint was the number 
of active lesions per patient per scan at six months, later 
extended to 12 and 16 months.58 Patients were evaluated 
every four weeks during the initial 24-week period, and again 
at 36, 48, and 64 weeks. The 44 µg treatment group showed Biologics: Targets & Therapy 2009:3 266
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significant effects on freedom from relapses compared to 
the 30 µg group at all time points. There was a 32% relative 
reduction in the proportion of relapse-free patients treated 
with 44 µg TIW at 24 weeks, and a 21% relative reduction at 
48 weeks (p = 0.003). There was a 27% relative reduction in 
relapse rates at 24 weeks in the 44 µg TIW treatment cohort 
(p = 0.022); these relapse rates were 0.29 for the 44 µg TIW 
group and 0.40 for the 30 µg weekly group, however the 
reduction in relapses with 44 µg TIW did not maintain signifi-
cance at 48 weeks. At 24 weeks, the 44 µg TIW group showed 
a significant effect on MRI lesions (p  0.0001). This effect 
was also maintained at 48 weeks (p  0.001). Injection site 
reactions, asymptomatic liver enzyme elevations, and altered 
leukocyte counts were more frequent in the 44 µg TIW arm 
compared to the once weekly 30 µg arm.
In 2005, an extension of the EVIDENCE trial was 
reported59 in which patients in the 30 µg IM weekly IFNβ-1a 
group were permitted to cross over to 44 µg SC TIW. The 
primary outcome measure was the annualized relapse rate 
compared to the rate prior to transition. Several secondary 
MRI endpoints were also included. The MRI evaluators 
remained blinded. Patients previously on 44 µg TIW were 
allowed to remain on that dose. The post-transitional relapse 
rate decreased from 0.64 to 0.32 for patients switching to 44 µg 
TIW (p  0.001) and from 0.46 to 0.34 for patients remaining 
on 44 µg TIW (p = 0.02). Patients converting to the higher 
dose regimen had fewer active T2 MRI lesions in comparison 
to pre-transition values (p = 0.02). There were no significant 
MRI changes in patients maintained on high dose therapy. 
Patients switching to high dose therapy were noted to have an 
increase in mild to moderately severe adverse events.
A multicenter, randomized open label Danish trial60 
recently compared IFNβ-1a (Rebif®) 22 µg once weekly to 
the standard dose of IFNβ-1b (Betaferon®) 250 µg every other 
day. Patients enrolled in this study had definite RRMS, EDSS 
scores of 0 to 5.5, and two relapses within the last two years. 
Blinding was not attempted in this trial except for MRI 
evaluations. Three hundred one patients were randomized 
to either dose regimen. A third cohort was included in this 
study, containing patients with newly diagnosed RRMS who 
refused randomization but were treated with 250 µg IFNβ-1b 
every other day. Annual relapse rates, time to first relapse, 
and time to sustained progression were virtually identical in 
the two arms of the randomized study. In the nonrandomized 
treatment group, the annual relapse rate was not significantly 
different, but there was a trend toward shorter time to 
progression. The conclusion of this study was that IFNβ-1b 
250 µg every other day was not clinically superior to IFNβ-1a 
22 µg once weekly, a surprising and uninterpretable finding 
in light of the INCOMIN and EVIDENCE trial results.
Safety and tolerability
The most common side effects of IFNβ therapy are flu-like 
symptoms, increased spasticity, hematologic and hepatic 
laboratory abnormalities, inflamed injection sites, cutaneous 
necrosis, and depression.61 Experience has shown that 
patient education about side effects prior to treatment, and 
proper management of adverse events, improves adherence 
to treatment.62,63 Injection site reactions are more common 
when beta interferon is administered SC compared to the 
IM route. These reactions are characterized by local pain, 
erythema, and induration. In the EVIDENCE trial,57 83% 
of patients on SC IFNβ-1a versus 28% on IM IFNβ-1a 
experienced injection site reactions. Koch-Henriksen and 
colleagues60 reported the equal occurrence of injection 
site reactions in patients treated SC with either IFNβ-1a or 
IFNβ-1b. However, an observational prospective study of 
306 Betaferon® and 148 Rebif® patients found significantly 
more pain-free days and fewer injection site reactions in 
the IFNβ-1b group.64
The cause of injection site reactions probably varies from 
one patient to another. Management strategies for treatment of 
these reactions include careful attention to aseptic technique, 
avoidance of intradermal injections, making sure the solution 
is completely dissolved and at room temperature, avoiding 
excessive sun exposure, local application of heat or cold, 
and use of nonsteroidal anti-inflammatory drugs (NSAIDS) 
to alleviate pain and prevent fever. Patients should be 
encouraged to keep a log of injection sites, making sure to 
alternate regularly to avoid skin breakdown. Injection site 
reactions usually diminish over a 3–6 month time period. 
Skin necrosis is a rare but serious complication of SC 
therapy, and to date no cases have been reported with the 
IM delivery route. Improper injection technique, including 
failure to alternate sites, has been shown to increase the risk 
of skin necrosis. If necrosis occurs, subcutaneous interferon 
should be discontinued and alternative therapy, including IM 
therapy, should be considered. Patients should be cautioned 
not to use topical steroids on these sites as they can delay 
recovery.61
Flu-like symptoms of chills, fatigue, headache, and 
myalgias can occur a few hours after administering IFNβ, and 
may persist for 24 hours or more. Kümpfel and colleagues65 
found IFN-β injections at night led to increased IL-6 levels 
and temperature, correlating with decreased cortisol levels 
and more intense systemic side effects when compared to Biologics: Targets & Therapy 2009:3 267
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morning injections, with acute effects moderating after six 
months. This variation in time of injection administration 
may assist some patients with tolerability. Clinical experience 
has shown flu-like symptoms to become less frequent in 
most patients within three months of beginning therapy. 
Gradual dose escalation, as well as taking NSAIDS, reduces 
the occurrence of flu-like symptoms.66 Occasionally patients 
treated with IFNβ may notice an increase in spasticity during 
initiation of treatment. This typically occurs in patients who 
already have increased muscle tone and known temperature 
sensitivity, usually within hours of treatment, and lasting 
for days. Management with NSAIDS or antispasticity 
medications is often effective. Cases of hypothyroidism 
and hyperthyroidism are occasionally reported in patients 
on interferon therapy, and may require stopping therapy or 
switching to a non-IFN agent such as glatiramer acetate.
There is conflicting evidence to date regarding the 
relationship of IFNβ treatment to depression. Patients with 
known depression prior to treatment should be monitored 
carefully, and initiation of an antidepressant at the time of 
treatment should be considered. One should caution patients 
and family members to watch for depressive symptoms, and 
alert the prescribing provider should they occur. If patients on 
IFNβ therapy develop signs or symptoms of a mood disorder, 
the IFNβ should be discontinued, and if symptoms persist, 
treatment with psychotherapy, antidepressants, or both may 
be required. Occasionally, treatment may be re-instituted 
without recurrence of the depression.
Patients on IFNβ therapy commonly develop transient 
elevations of liver enzymes (AST and ALT), neutropenia, and 
less commonly, anemia. Tremlett and colleagues67 performed 
a retrospective chart review of 844 MS patients treated with 
IFNβ-1a or IFNβ-1b therapy, and found that 37% of patients 
developed new elevations of ALT. The effect of IM IFN 
was less than that of the SC IFNs on ALT levels. To date, 
two patients have been described with liver failure requir-
ing transplantation,68 one of whom was concurrently taking 
nefazodone, another potentially hepatotoxic medication.69 
No potential confounders could be identified in the second 
patient.
Francis and colleagues68 reviewed a pooled database 
of patients treated with IFNβ-1a, and found ALT eleva-
tions in 59% of patients on IFNβ-1a 44 µg TIW and 40% 
of patients taking IFNβ-1a 30 µg per week. More than 
50% of the elevations occurred within three months, 75% 
occurred within six months, and most elevations remitted 
spontaneously. Men were found to be more susceptible than 
women to liver enzyme elevations. Dosage reductions were 
necessary in 5% of treated patients, and universally led to 
normalization of values. Propionic acid derivatives taken 
concomitantly were the only medications shown to statisti-
cally be associated with increased risk of liver dysfunction. 
The authors recommended liver function analysis prior to 
treatment and at 1, 3, and 6 months, with dose reductions 
for patients with ALT values of 5–20 times normal and 
discontinuation of treatment for those whose ALT levels 
are over 20 times normal. Despite these caveats, high dose 
IFNβ therapy is reasonably well tolerated, with an acceptable 
safety profile, as its continued long-term use in the MS 
population attests.
Neutralizing antibodies
The effect of neutralizing antibodies (NAbs) on IFNβ therapy 
remains a topic of controversy. In the IFNβ-1a (Avonex®) 
trial,37 22% of patients developed NAbs; however an effect 
on endpoint measures could not be ascertained because of the 
short duration of the study. After reformulation, this product 
led to development of NAbs in only 5%–7% of patients.56,57 
In the PRISMS-4 study,49 low dose interferon 22 µg TIW 
was associated with the development of NAbs in 23.7% of 
patients while in the 44 µg TIW group 14.3% developed 
NAbs. Though no clinical effect was noted at two years, a 
reduction in clinical outcome measures was found at four 
years. In the multicenter trial of IFNβ-1b in RRMS, 38% of 
patients developed NAbs by the third year with a noticeable 
attenuation of treatment effect. Perini and colleagues70 found 
40% of β-1b patients, 6.7% of IM IFNβ-1a, and 27% of SC 
IFNβ-1a patients developed antibodies. This study found 
the presence of high titers of both binding and neutralizing 
antibodies to be indicative of loss of treatment effect. There 
are also data suggesting that Nab titers can revert to negative 
over time.71 This was shown in the IFNβ-1b follow-up 
study,72 in which 80% of NAb positive patients converted 
to antibody-negative status after 8 years despite continued 
therapy. NAbs to one IFNβ product cross-react with the 
others,73 so switching therapy to another IFNβ is not likely 
to be an effective strategy. In a recent phase III trial of a new 
and less immunogenic formulation of SC IFNβ-1a (Rebif®), 
an interim analysis74 showed reduced antibody formation and 
improved tolerability. Publication of the results of this trial 
is awaited with interest.
The American Academy of Neurology recently reported 
the recommendations of a subcommittee focusing on the 
effect of NAbs on clinical and radiologic outcomes.75 The 
committee concurred that there is probably a reduction in 
efficacy of treatment because of NAbs. They also concurred Biologics: Targets & Therapy 2009:3 268
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that there is likely to be greater antibody production in 
response to IFNβ-1b than to IFNβ-1a, and that IM IFNβ-1a 
is clearly less immunogenic than other interferon therapies. 
Despite the consistent finding of NAb levels greater than 
1:200 being associated with a reduction of efficacy, the 
committee was unable to make definite recommendations for 
changing therapy. This report highlights the fact that many 
questions remain unanswered in regard to the NAb issue.
The differences in assays used to measure NAbs, 
criteria for NAb positivity, and varying clinical assessment 
measures, make comparison between the studies difficult, if 
not impossible. Until clear data are available regarding the 
importance of neutralizing antibodies, decisions to change 
treatment should be based on the clinical picture. If a patient 
continues to have relapses despite IFNβ treatment, the 
physician should consider testing for NAbs and switching 
to another therapy. If NAbs are detected at a titer of 1:20 or 
greater on repeated testing, a non-interferon therapy such 
as glatiramer acetate should be considered. However, in a 
patient doing well clinically, there currently appears to be 
no benefit in testing for NAbs. The value of periodic MRI 
evaluation in the absence of clinical worsening has not been 
established.
Quality of life
Studies of IFNβ in the treatment of MS have shown benefit 
in relapse frequency and severity, as well as a reduction in 
hospitalizations. MS typically affects patients in the most 
productive years of their lives, and IFNβ therapy allows 
for fewer interruptions in activities of daily living. These 
studies have also shown excellent tolerability and relatively 
benign side effect profiles. The key to successful adherence 
to treatment is proper education about side effects and their 
management.62,63 Patients should be aware that beta interferon 
therapy is designated as pregnancy category C, meaning that 
spontaneous abortions have been observed in IFNβ-treated 
animals. A longitudinal, controlled cohort study found a 
decrease in mean birth weight and an increased risk of fetal 
loss in interferon exposed patients, even after correcting for 
potential cofounders.76 Patients are encouraged not to take 
any of the IFNβ products while breast feeding because the 
risks of transmission through breast milk are unknown.
A recent study showed that depression is the principal 
factor affecting quality of life in patients with MS.77 The effect 
of interferon therapy on depression remains controversial. 
Symptoms such as suicidal ideation, decreased interest, feelings 
of guilt, loss of energy and concentration, and change in 
appetite may be signs of undiagnosed depression. Patients with 
these symptoms may require treatment with antidepressants, 
psychotherapy, or both and should be treated accordingly.
Conclusions and recommendations
The past decade has brought broader treatment options 
to physicians caring for patients with MS. Numerous 
randomized controlled trials of IFNβ have been published 
(Tables 1 and 2), confirming their efficacy on relapse rates, 
disease severity, and MRI outcomes. Unfortunately, long-term 
follow up assessments are few, and fraught with limitations. 
Those long-term studies that are available demonstrate that 
atrophy and disease progression continue despite early 
improvement in clinical and MRI outcomes. This suggests 
that other processes, in addition to inflammation, underlie 
the pathogenesis of MS, and indicate a need for additional 
treatment options. Until then, the current studies support 
treatment with IFNβ at the time of diagnosis of MS, as shown 
by the inability of placebo cohorts treated later to catch up 
to patients originally receiving interferon.
The relative importance of dose, frequency, and route 
of administration remains unclear. This is underlined by the 
recent study of double dose IFNβ-1b and lack of statistical 
superiority found in patients treated with 500 µg every other 
day compared to 250 µg every other day, and to glatiramer 
acetate, on the risk of relapses.78 The relapse rate was very 
low in all study arms. Currently it appears that both dose and 
frequency of administration are important, and the effects of 
each cannot clearly be distinguished. Decisions about the 
choice of an IFNβ in each individual case should be made 
in the context of an informed discussion between physician 
and patient. Treatment should be customized to the patient 
with regard to frequency and route of administration, as well 
as side effects, in order to maximize compliance.
The decision to treat after a first demyelinating event 
(CIS), and before the diagnosis of MS is established, is also 
not obvious. The CHAMPS (35% compared to 50%), ETOMS 
(34% compared to 45%), and BENEFIT (15% compared to 
31%) studies all showed modest benefit at 2 years in preventing 
patients with CIS from having a second relapse. Those patients 
who have polysymptomatic disease and a larger T2 lesion 
load on MRI at the time of their first demyelinating event are 
more likely to convert to definite MS. Clinical suspicion and 
careful follow-up seems to be the best option in these cases, 
given that the alternative is prescribing a potentially unpleasant 
injectable medication that the patient may not need. There is no 
evidence to indicate that waiting a few months for the patient 
to meet the McDonald criteria for definite MS increases future 
risk compared to treating at the first sign of CIS. Furthermore, Biologics: Targets & Therapy 2009:3 269
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treatment at the CIS stage removes patients from the pool of 
potential RRMS subjects eligible for clinical trials. For these 
reasons, it is our practice to follow these patients with frequent 
MRIs and clinical examinations every 3–6 months.
The issue of NAbs also needs to be clarified. Any decision to 
change treatment remains a clinical one based on examination, 
history, and imaging. If a patient is doing well on treatment, 
knowing the NAb status is of little value. If a patient is doing 
poorly on treatment, it is time to change, regardless of NAbs.
Our understanding of MS with regard to pathophysi-
ology and treatment is just beginning, and the prospects 
for further studies are exciting. The three available IFNβ 
preparations represent a major breakthrough in the history 
of MS therapy. In addition, by a process analagous to reverse 
engineering, they have given rise to a plethora of labora-
tory studies that have increased our understanding of MS 
pathogenesis and the mechanism of IFN action. However, 
numerous other compounds that may be more effective are 
currently in phase II and phase III clinical trials. Moreo-
ver, several of these are administered orally, an obvious 
advantage in terms of patient acceptance and compliance. 
Combination therapy also holds promise for MS, although 
well-designed and adequately controlled studies are difficult 
to conduct. Fortunately, placebo-controlled clinical trials are 
still considered ethical, at least under certain circumstances 
such as time-limited phase II studies and trials in SPMS and 
PPMS.79 Clinical trials of MS therapy continue to become 
increasingly complex, and a combination of placebo-control-
led studies, trials comparing new agents to the best available 
current therapy, and combination or add-on studies will be 
necessary to provide the information needed to manage the 
broad spectrum of patients with this devastating disease
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